Sosei Group has announced that the Ultibro Breezhaler indacaterol/glycopyrronium DPI has been added to the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of COPD. Novartis launched Ultibro Breezhaler and Seebri Breezhaler in China in March 2019.
Sosei Heptares President and CEO Shinichi Tamura commented, “We are pleased that COPD patients in China will have improved access to this novel inhaled product through the inclusion in the 2019 NRDL. COPD is the fourth leading cause of death in China and a major public-health problem affecting nearly 100 million people. Ultibro has shown to be effective in managing COPD symptoms to improve lung function and quality of life and to reduce the incidence of acute exacerbations. Broadened access to new COPD treatments in China could significantly improve the lives of those patients most in need.”
Read the Sosei Heptares press release.
